Previous close | 72.50 |
Open | 73.28 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 72.71 - 72.83 |
52-week range | 57.97 - 81.40 |
Volume | |
Avg. volume | 354,443 |
Market cap | 1.2B |
Beta (5Y monthly) | 0.39 |
PE ratio (TTM) | 0.26 |
EPS (TTM) | 2.82 |
Earnings date | 26 Jul 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
It's easy to match the overall market return by buying an index fund. When you buy individual stocks, you can make...
Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseasesCAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced a two-year extension to the collaboration with Bristol Myers Squibb (NYSE: BMY) under which the parties may research, develop, and commercialize autologous and allogeneic alpha-beta T cell medicines for the treatment of cancer
Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted immune medicines, announced today that it has entered a multi-year strategic collaboration with Bristol Myers Squibb (NYSE: BMY) to develop tolerizing vaccines for up to three autoimmune diseases. The collaboration aims to develop efficacious, selective, and durable treatments for patients suffering from autoimmune disease by resetting the immune system.